Guangzhou Coretech Pharmaceutical Co., Ltd. is a chemical pharmaceutical company located in Guangzhou, China, focusing on anti-tumor drugs. It is hereinafter referred to as "Coretech Pharmaceutical."

About Renal Cell Carcinoma (RCC)

           Renal cell carcinoma ( RCC ) is a highly malignant tumor in the urinary system and one of the most common tumors. It is also known as renal adenoma and accounts for 80% ～ 90% of renal malignant tumors. According to surveys, renal cell carcinoma ranks second among urological and reproductive system tumors in China, second only to bladder tumors, accounting for 2% ～ 3% of adult malignant tumors and 20% of pediatric malignant tumors. There is a significant difference in incidence rates between men and women. According to statistics, the male-to-female ratio is 2:1 . The incidence of renal cell carcinoma increases with age. Data show that the high-incidence age of renal cell carcinoma is 40 ～ 55 years old. In addition, the incidence of renal cell carcinoma varies significantly internationally, with significantly higher rates in European and American countries than in Asian countries. The incidence rates in countries such as Japan and India are relatively low. The incidence rate in urban areas is higher than that in rural areas. 2020 New global cases in RCC exceeded 43 ten thousand cases, with 18 ten thousand people dying from the disease. In China, 2020 new cases of renal cancer in the country were approximately 74000 cases, accounting for approximately 17.0% 。

of global new cases.

   Gastrointestinal stromal tumors (GISTs) are tumors with varying malignant potential, originating from the smooth muscle layer of the digestive tract wall, mainly growing into the lumen. They are found in various parts of the digestive tract, including the stomach (approximately 60%–65%, mostly in the upper part of the stomach), small intestine (20%–25%, mainly in the duodenum and proximal jejunum), colon, and rectum (including low GISTs, mainly in the distal rectum), and esophagus (1%). The clinical incidence is 8/1000,000, with the highest incidence in the 70–79 age group. Micro-GISTs with a diameter of <1 cm occur in 20%–30% of elderly people. In addition, GISTs have the highest incidence in the stomach and small intestine, accounting for 50%–60% and 30%–35%, respectively. The incidence in the colorectum and esophagus is 5% and <1%, respectively. GISTs have a potential for malignant transformation and recurrence and metastasis. 10%–30% are malignant tumors, with a 5-year survival rate of approximately 79%. Advanced age, Black race, male sex, and high-risk grading are independent risk factors for low survival rates.

The clinical manifestations of patients are related to the tumor location, size, and growth direction. Because they are located submucosally and are not invasive, most patients do not show corresponding symptoms until the late stage. They usually manifest as abdominal pain, abdominal distension, etc. Patients located at the gastroesophageal junction may experience dysphagia, and patients with submucosal growth may develop ulcers, manifesting as gastrointestinal bleeding and anemia. Although more than half of micro-stromal tumors exhibit benign tumor characteristics, as gastrointestinal stromal tumors increase in size, some may become malignant and metastasize. In more than 50% of patients with gastrointestinal stromal tumors who seek medical attention for the first time, liver metastasis and peritoneal metastasis have already occurred, with 65% of patients metastasizing to the liver, thus proving fatal.

About Pancreatic Neuroendocrine Tumors (pNETs)

   Pancreatic neuroendocrine tumors (pNETs) are a group of rare and highly heterogeneous tumors originating from neuroendocrine islet cells in the pancreas. They account for only 5% of pancreatic tumors, making them a rare malignancy. The annual incidence rate is 2-3 per 100,000. pNETs are classified as functional or non-functional. Functional pNETs exhibit clinical symptoms based on the hormone secreted; non-functional pNETs lack typical symptoms and signs, making early diagnosis difficult. pNETs tend to develop relatively slowly. Early diagnosis and timely surgery can lead to a favorable prognosis. CT and MRI have become the primary imaging methods for evaluating pancreatic tumors, offering significant value in tumor characterization and prognosis assessment.

Guangzhou Corete Pharmaceutical Co., Ltd., a subsidiary of Qi Xi Group, was established in 2013. It is a modern, comprehensive pharmaceutical company integrating R&D, production, and marketing. Its R&D center is located in Guangzhou High-tech Industrial Development Zone, and its self-built factory is located in Yonghe Development Zone, Huangpu District, Guangzhou, covering an area of approximately 13,000 square meters. The factory includes four main buildings: an oral solid preparation workshop, a raw material workshop, a Class A warehouse, and an environmental protection station.

After years of development, the company has assembled a research and development team with high educational backgrounds and strong technical capabilities, and established a complete GMP and EHS management system . It has successfully overcome the technical barriers of more than ten anti-tumor drugs, including lenalidomide, erlotinib, imatinib, and sunitinib, developing raw materials and formulations with its own production advantages.

Corete Pharmaceutical adheres to the mission of "Life First, Quality-Based" and the quality policy of "Striving for Excellence, Creating Better Health with Superior Quality," continuously implementing quality objectives. The company obtained its first "Drug Production License" in 2022. The current production license scope includes raw materials, tablets, and hard capsules. In 2023, it passed the GMP compliance inspection for tablets and hard capsules. As a key link in the health industry, Corete Pharmaceutical aims to reduce medical expenses for cancer patients, providing safe, effective, and affordable high-quality medicines while alleviating the medical burden on the country.